Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER’s Cost-Effectiveness Estimates

Rachel Milstein Breslau, Joshua T. Cohen, Daniel A. Ollendorf and Peter J. Neumann ()
Additional contact information
Rachel Milstein Breslau: Tufts Medical Center
Joshua T. Cohen: Tufts Medical Center
Daniel A. Ollendorf: Tufts Medical Center
Peter J. Neumann: Tufts Medical Center

PharmacoEconomics - Open, 2022, vol. 6, issue 6, No 11, 893-895

Date: 2022
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-022-00358-y Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:6:y:2022:i:6:d:10.1007_s41669-022-00358-y

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-022-00358-y

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().